Advisory Board September 28, 2022
Lecanemab, an experimental Alzheimer’s drug developed by Eisai and Biogen, slowed cognitive and functional decline by 27% compared to a placebo in a new study—results that the drugmakers said were “highly statistically significant.”
3 big questions to ask after FDA’s historic Alzheimer’s drug approval
Details on the study
Similar to Aduhelm, Alzheimer’s drug lecanemab reduces abnormal clumps of beta amyloid, proteins that are typically a sign of Alzheimer’s disease.
According to a press release, the study—called CLARITY-AD—enrolled 1,795 patients with mild cognitive impairment caused by Alzheimer’s disease, or early-stage Alzheimer’s. Roughly a quarter of the participants were Hispanic and African American.
The patients were then tested using the Clinical Dementia Rating sum of boxes (CDR-SB), which measures six domains of...